Inovio Pharmaceuticals (NSDQ:INO) said today that it priced an offering of $65 million of 6.5% convertible senior notes due 2024. The Plymouth Meeting, Penn.-based company also gave initial purchasers a 13-day option to buy up to an additional $20 million in notes. Inovio expects to reel in roughly $62.7 million in net proceeds from the offering […]
Delcath wins approval for Chemosat in Brazil
Delcath Systems (OTC:DCTH) said today that it won medical device approval for its Chemosat hepatic delivery system from the national health authority in Brazil. The New York-based company plans to market and sell Chemosat in Brazil for the percutaneous intra-arterial administration of melphalan hydrochloride to the liver with subsequent extracorporeal filtration of blood. Delcath will work with […]
BTG touts use of radiopaque drug-eluting bead
BTG (LON:BTG) said this month that an Australian patient was treated with its radiopaque drug-eluting bead. The DC Bead Lumi product is the first commercial drug-eluting bead that can be loaded with doxorubicin or irinotecan to treat tumors in patients with hepatocellular carcinoma and liver metastases from colorectal cancer, according to BTG. The beads’ radiopacity enable […]
Proteus debuts digital cancer drug
Proteus Digital Health said today that the first cancer patients were treated using its digital oncology therapy, which combines oral chemotherapy with an ingestible sensor. Patients with stage 3 and 4 colorectal cancer at the University of Minnesota Health and Fairview Health Services were treated with digital capecitabine. The Redwood City, Calif.-based company plans to […]
Delcath inks European licensing deal for Chemosat
Delcath Systems (OTC:DCTH) said this week that it inked a licensing deal with Germany-based medac for the commercialization of Chemosat in Europe. According to the terms of the seven-year agreement, Delcath’s European subsidiary will exclusively license its Chemosat system to Medac for sale in the EU, Norway, Liechtenstein, Switzerland and the UK. Medac is slated […]
Novocure touts analysis of pivotal glioblastoma trial results
Novocure (NSDQ:NVCR) today touted the results of a retrospective sub-group analysis of its EF-14 Phase III pivotal trial in patients with newly diagnosed glioblastoma. The analysis, which was published in the Journal of Neuro-Oncology, demonstrated that more time on Novocure’s Optune device predicted increased survival in people who received Optune plus temozolomide compared to those who received […]
Boston Scientific puts $4B on the table for BTG’s interventional portfolio
Boston Scientific (NYSE:BSX) said today that it agreed to offer $4.24 billion to acquire British medical device maker BTG (LON:BTG) and its portfolio of interventional drug-device therapies. The Marlborough, Mass.-based company said that its acquisition of BTG will augment Boston Scientific’s capabilities in the treatment of cancer and pulmonary embolism. “We are confident that the addition of these therapies […]
OncoSec shares fall on preliminary data from skin cancer trial
Shares in OncoSec Medical (NSDQ:ONCS) fell nearly -60% this morning after the company revealed preliminary data from its Phase IIb trial of intratumoral delivery of Tavo in people with unresectable, advanced melanoma. OncoSec’s lead product, Tavo, uses electroporation to deliver IL-12 directly into a patient’s tumor, triggering an immune response. As of Sept. 1, 21 people […]
Mustang Bio studies intraventricular delivery of immunotherapy in Ph1 trial
Mustang Bio (NSDQ:MBIO) said today that it launched a Phase I trial to evaluate the safety and efficacy of intraventricular delivery of CAR T-cells to the brains of people with HER2-positive breast cancer. The 21-patient trial’s primary goal is to determine the recommended dosing regimen for a Phase II trial. Secondary objectives include evaluating the […]
Delcath registers $100m offering
Delcath Systems (NSDQ:DCTH) registered a $100 million offering with the SEC this week to support the development of its system designed to administer high-dose chemotherapy to the liver. The company’s product, melphalan hydrochloride for injection for use with the Delcath hepatic delivery system, won CE Mark clearance in Europe in 2012 and is under consideration by […]
- 1
- 2
- 3
- …
- 25
- Next Page »
Drug Delivery Business News
@DrugDeliveryNow
LinkedIn